This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cerebrotendinous xanthomatosis

Authoring team

Cerebrotendinous xanthomatosis (CTX)

  • is a rare autosomal recessive disorder

  • due to a efective enzyme in bile acid synthesis pathway with deposition of cholestanol and cholesterol in brain, tendons, soft tissues and eyes leading to cerebellar dysfunction, early cataract formation, tendon, and soft tissue xanthomas

  • the disease is potentially treatable with chenodeoxycholic acid

  • CTX is characterized by defective sterol 27-hydroxylase enzyme which is responsible for conversion of cholesterol into bile acids (cholic and chenodeoxycholic acid)

  • diagnosis is by the characteristic combination of neurological, ocular and musculoskeletal symptoms supplemented by neuroimaging and biochemical results

  • early diagnosis and treatment is essential to prevent the neurological sequelae of the disease
    • treatment consists of chenodeoxycholic acid which suppresses the formation of cholestanol

Reference:

  1. Bjorkhem I. Cerebrotendinous xanthomatosis. Curr Opin Lipidol. 2013;24:283-287.
  2. Lionnet C et al. Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects. Rev Neurol (Paris). Jun-Jul 2014;170(6-7):445-53.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page